Iridex (IRIX) Debt to Equity (2020 - 2021)

Iridex (IRIX) recorded quarterly Debt to Equity of $0.09 in Q2 2021, up 18.45% quarter-over-quarter from $0.07 in Q1 2021.

Iridex (IRIX) Debt to Equity (2020 - 2021) Analysis & Trends

Iridex's Debt to Equity history runs 2 years deep, the most recent figure standing at $0.09 for Q2 2021.

In Q2 2021, Debt to Equity changed N/A year-over-year to $0.09; the TTM figure through Apr 2021 stood at $0.09 (changed N/A YoY), while the FY2021 annual figure was $0.07, changed N/A from the prior year.
Debt to Equity was $0.09 for Q2 2021 at Iridex, up from $0.07 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.09 in Q3 2020 to a low of $0.07 in Q1 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Iridex	19.91 Mn	15.31 Mn	4.74 Mn	-

Historic Data

Download Data

Date	Value
Apr 3, 2021	0.09
Jan 2, 2021	0.07
Sep 26, 2020	0.09